Maarten L. Janmaat

3.2k total citations · 1 hit paper
28 papers, 2.4k citations indexed

About

Maarten L. Janmaat is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Maarten L. Janmaat has authored 28 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Molecular Biology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Maarten L. Janmaat's work include Monoclonal and Polyclonal Antibodies Research (10 papers), Lung Cancer Treatments and Mutations (6 papers) and Phagocytosis and Immune Regulation (4 papers). Maarten L. Janmaat is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), Lung Cancer Treatments and Mutations (6 papers) and Phagocytosis and Immune Regulation (4 papers). Maarten L. Janmaat collaborates with scholars based in Netherlands, United States and Denmark. Maarten L. Janmaat's co-authors include Paul W.H.I. Parren, Janice M. Reichert, Aran F. Labrijn, Giuseppe Giaccone, José Antonio Rodríguez, Frank A.E. Kruyt, Mariëlle I. Gallegos-Ruiz, Tuna Mutis, Niels W.C.J. van de Donk and Tahamtan Ahmadi and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Maarten L. Janmaat

27 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bispecific antibodies: a mechanistic review of the pipeline

2019 887 citations Aran F. Labrijn, Maarten L. Janmaat et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maarten L. Janmaat Netherlands	17	1.3k	1.0k	726	567	525	28	2.4k
M. S. Berger United States	19	948 0.8×	857 0.8×	373 0.5×	342 0.6×	316 0.6×	37	2.1k
Helmout Modjtahedi United Kingdom	30	1.4k 1.1×	1.1k 1.0×	544 0.7×	268 0.5×	548 1.0×	81	2.5k
Daniel Ajona Spain	27	944 0.7×	913 0.9×	417 0.6×	1.5k 2.6×	566 1.1×	56	2.9k
Tiffany K. Ricks United States	15	781 0.6×	542 0.5×	450 0.6×	434 0.8×	206 0.4×	21	1.8k
Pina M. Cardarelli United States	25	1.1k 0.9×	1.0k 1.0×	756 1.0×	1.1k 1.9×	146 0.3×	66	2.9k
Jennifer R. Diamond United States	26	2.0k 1.6×	998 1.0×	400 0.6×	466 0.8×	756 1.4×	136	3.0k
Jan Pinkas United States	23	1.5k 1.2×	940 0.9×	783 1.1×	275 0.5×	124 0.2×	71	2.3k
Diane L. Persons United States	29	1.3k 1.0×	1.4k 1.3×	412 0.6×	295 0.5×	409 0.8×	64	3.1k
Marie Prewett United States	18	1.7k 1.3×	1.4k 1.4×	661 0.9×	274 0.5×	816 1.6×	34	2.9k
Ralf Brandt United States	18	2.5k 2.0×	1.9k 1.8×	632 0.9×	526 0.9×	1.1k 2.0×	27	4.0k

Countries citing papers authored by Maarten L. Janmaat

Since Specialization

Citations

This map shows the geographic impact of Maarten L. Janmaat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maarten L. Janmaat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maarten L. Janmaat more than expected).

Fields of papers citing papers by Maarten L. Janmaat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maarten L. Janmaat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maarten L. Janmaat. The network helps show where Maarten L. Janmaat may publish in the future.

Co-authorship network of co-authors of Maarten L. Janmaat

This figure shows the co-authorship network connecting the top 25 collaborators of Maarten L. Janmaat. A scholar is included among the top collaborators of Maarten L. Janmaat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maarten L. Janmaat. Maarten L. Janmaat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hiemstra, Ida H., Kim C. M. Santegoets, Maarten L. Janmaat, et al.. (2023). Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity. EBioMedicine. 93. 104663–104663. 18 indexed citations

Kemper, Kristel, Péter Boross, Mischa Houtkamp, et al.. (2022). Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models. Life Science Alliance. 5(11). e202201481–e202201481. 3 indexed citations

Boshuizen, Julia, Nora Pencheva, Oscar Krijgsman, et al.. (2021). Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade. Cancer Research. 81(7). 1775–1787. 48 indexed citations

Hiemstra, Ida H., Maarten L. Janmaat, Péter Boross, et al.. (2020). Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models. Blood. 136(Supplement 1). 19–20.

Labrijn, Aran F., Maarten L. Janmaat, Janice M. Reichert, & Paul W.H.I. Parren. (2019). Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery. 18(8). 585–608. 887 indexed citations breakdown →

Koopman, Louise A., Mikkel G. Terp, Gijs G. Zom, et al.. (2019). Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 4(21). 46 indexed citations

Boshuizen, Julia, Louise A. Koopman, Oscar Krijgsman, et al.. (2018). Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nature Medicine. 24(2). 203–212. 164 indexed citations

Losen, Mario, Aran F. Labrijn, Vivianne van Kranen-Mastenbroek, et al.. (2017). Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys. Scientific Reports. 7(1). 992–992. 8 indexed citations

Donk, Niels W.C.J. van de, Maarten L. Janmaat, Tuna Mutis, et al.. (2016). Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunological Reviews. 270(1). 95–112. 237 indexed citations

10.

Breij, Esther C.W., Sandra Verploegen, Andreas Lingnau, et al.. (2015). Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers.. Journal of Clinical Oncology. 33(15_suppl). 3066–3066. 6 indexed citations

11.

Janmaat, Maarten L., et al.. (2009). Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines. Anti-Cancer Drugs. 20(6). 450–460. 26 indexed citations

12.

Bosch, Linda J.W., et al.. (2009). Basic fibroblast growth factor-mediated overexpression of vascular endothelial growth factor in 1F6 human melanoma cells is regulated by activation of PI-3K and p38 MAPK.. SHILAP Revista de lepidopterología. 31(3). 179–90. 4 indexed citations

13.

Janmaat, Maarten L., et al.. (2007). Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochemical Pharmacology. 75(2). 427–437. 34 indexed citations

14.

Giaccone, Giuseppe, Maarten L. Janmaat, Mariëlle Gallegos Ruiz, et al.. (2005). P-485 EGFR mutations do not accurately predict response to erlotinib in first-line monotherapy treatment of advanced non-small-cell lung cancer. Lung Cancer. 49. S244–S244. 3 indexed citations

15.

Janmaat, Maarten L., José Antonio Rodríguez, Mariëlle I. Gallegos-Ruiz, Frank A.E. Kruyt, & Giuseppe Giaccone. (2005). Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol‐3 kinase pathways in non‐small cell lung cancer cells. International Journal of Cancer. 118(1). 209–214. 130 indexed citations

16.

Giaccone, Giuseppe, T. Lechevalier, Nicholas Thatcher, et al.. (2005). A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer. Journal of Clinical Oncology. 23(16_suppl). 7073–7073. 25 indexed citations

17.

Janmaat, Maarten L., José Antonio Rodríguez, José Jimeno, Frank A.E. Kruyt, & Giuseppe Giaccone. (2005). Kahalalide F Induces Necrosis-Like Cell Death that Involves Depletion of ErbB3 and Inhibition of Akt Signaling. Molecular Pharmacology. 68(2). 502–510. 81 indexed citations

18.

Janmaat, Maarten L., et al.. (2004). 560 Kahalalide F (KF) induces apoptosis-independent cell death that involves ErbB3 downregulation and inhibition of Akt signalling. European Journal of Cancer Supplements. 2(8). 170–170. 1 indexed citations

19.

Janmaat, Maarten L. & Giuseppe Giaccone. (2003). The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.. PubMed. 39 Suppl C. 61–80. 67 indexed citations

20.

Wang, Xuemin, Maarten L. Janmaat, Anne Beugnet, F. Paulin, & Christopher G. Proud. (2002). Evidence that the dephosphorylation of Ser535 in the ∊-subunit of eukaryotic initiation factor (eIF) 2B is insufficient for the activation of eIF2B by insulin. Biochemical Journal. 367(2). 475–481. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact